BioCryst Pharmaceuticals, Inc. (BCRX)
8.47
-0.05
(-0.59%)
USD |
NASDAQ |
Oct 30, 16:00
8.465
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Price : 8.47 for Oct. 30, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.55 | 8.617 | 8.38 | 8.47 | 3.527M |
| Oct 29, 2026 | 8.45 | 8.56 | 8.39 | 8.52 | 4.519M |
| Oct 28, 2026 | 8.05 | 8.445 | 8.005 | 8.37 | 3.937M |
| Oct 27, 2026 | 7.925 | 8.12 | 7.81 | 8.10 | 8.753M |
| Oct 26, 2026 | 7.69 | 8.00 | 7.66 | 7.88 | 4.381M |
| Oct 23, 2026 | 7.71 | 7.764 | 7.52 | 7.65 | 2.746M |
| Oct 22, 2026 | 7.78 | 7.88 | 7.66 | 7.78 | 4.806M |
| Oct 21, 2026 | 8.04 | 8.05 | 7.73 | 7.75 | 5.034M |
| Oct 20, 2026 | 8.11 | 8.13 | 7.84 | 7.94 | 8.455M |
| Oct 19, 2026 | 7.77 | 8.09 | 7.77 | 8.07 | 9.774M |
| Oct 16, 2026 | 7.96 | 8.015 | 7.74 | 7.79 | 4.431M |
| Oct 15, 2026 | 8.105 | 8.24 | 7.945 | 8.02 | 4.504M |
| Oct 14, 2026 | 8.02 | 8.18 | 7.97 | 8.05 | 5.650M |
| Oct 13, 2026 | 8.22 | 8.315 | 8.06 | 8.07 | 3.043M |
| Oct 12, 2026 | 8.49 | 8.55 | 8.24 | 8.36 | 3.467M |
| Oct 09, 2026 | 8.27 | 8.595 | 8.27 | 8.55 | 2.308M |
| Oct 08, 2026 | 8.36 | 8.40 | 8.13 | 8.29 | 5.122M |
| Oct 07, 2026 | 7.91 | 8.425 | 7.86 | 8.40 | 5.123M |
| Oct 06, 2026 | 8.15 | 8.15 | 7.87 | 7.95 | 3.944M |
| Oct 05, 2026 | 8.17 | 8.25 | 7.915 | 8.10 | 4.712M |
| Oct 02, 2026 | 8.12 | 8.20 | 7.92 | 8.17 | 6.149M |
| Oct 01, 2026 | 8.30 | 8.38 | 8.065 | 8.12 | 6.870M |
| Sep 30, 2026 | 8.28 | 8.42 | 8.184 | 8.33 | 13.10M |
| Sep 29, 2026 | 8.42 | 8.50 | 8.22 | 8.27 | 5.006M |
| Sep 28, 2026 | 8.555 | 8.66 | 8.335 | 8.47 | 4.355M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Amgen, Inc. | 466.01 |
| Halozyme Therapeutics, Inc. | 130.91 |
| Neurocrine Biosciences, Inc. | 146.10 |
| Agenus, Inc. | 6.84 |
| Anika Therapeutics, Inc. | 20.95 |
Price Related Metrics
| PS Ratio | 2.131 |
| PEG Ratio | -0.0074 |
| Price to Free Cash Flow | 5.626 |
| Earnings Yield | -17.76% |
| Market Cap | 2.162B |
| PEGY Ratio | -0.0074 |
| Operating PE Ratio | 5.212 |
| Normalized PE Ratio | 15.17 |